KEYTRUDA 25 mg/mL concentrate for solution for infusion, PRT3789
PRT3789-02
Phase 2 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, PRT3789 for non-small cell lung cancer (NSCLC), Esophageal Cancer, Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation is a Phase 2 program (small_molecule) at Prelude Therapeutics Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Prelude Therapeutics Inc
- Indication
- non-small cell lung cancer (NSCLC), Esophageal Cancer, Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active